<DOC>
	<DOCNO>NCT00900146</DOCNO>
	<brief_summary>This four month dose range study follow 24 48 month extension select dose characterize safety efficacy injectable IL-1B ( interleukin 1 , beta ) antagonist canakinumab treatment patient Type 2 diabetes mellitus ( T2DM ) already treat maximum dose metformin .</brief_summary>
	<brief_title>Dose Finding , Safety Efficacy Monthly Subcutaneous Canakinumab Administration Metformin Monotherapy Treated Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients must document diagnosis Type 2 diabetes confirm World Health Organization ( WHO ) criteria either FPG≥ 7.0 mmol/l ( 126 mg/dl ) Oral glucose tolerance test ( OGTT ) test 2hour PG ≥ 11.1 mmol/l ( 200 mg/dl ) . 2 . Patients must : naïve antidiabetes drug therapy ( except short term treatment course insulin connection hospitalization , etc . ) meet protocol specify Glycosylated hemoglobin / hemoglobin A1c ( HbA1c ) criterion eligible metformin monotherapy OR stable metformin monotherapy treatment least three month Screening meet protocol specify HbA1c criterion take metformin first treatment antidiabetes drug therapy OR take AGI first antidiabetes drug therapy ( except short term treatment course insulin connection hospitalization , etc ) meet protocol specify HbA1c criterion eligible metformin monotherapy 3 . Patients must morning fast plasma glucose result &lt; 180 mg/dl Visit 3 ( Month 1 ) analyze Central Laboratory . 4 . Were daily dose metformin ≥ 1000 mg ( less accord local regulation ) 1 . Type 1 diabetes , diabetes result pancreatic injury secondary form diabetes . 2 . Any following significant laboratory abnormality : Serum Glutamic acid decarboxylase ( GAD ) antibody positivity Clinically significant Thyroid stimulate hormone ( TSH ) outside normal range Screening Renal function indicate high risk metformin use , include serum creatinine concentration ( ≥1.5 mg/dL male , ≥1.4 mg/dL female ) evidence abnormal creatinine clearance . Alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2 x upper limit normal ( ULN ) , total bilirubin &gt; 2 x ULN and/or direct bilirubin &gt; ULN Screening , confirm repeat measure within one week . 3 . History current finding active pulmonary disease evidence history positive purify protein derivative ( PPD ) , QuantiFERONTB Gold ( QFTG ) , AFB sputum positive PPD follow positive chest xray QFTG , ongoing antibiotic treatment latent TB . 4 . Risk factor TB define protocol 5 . Known presence suspicion active recurrent bacterial , fungal viral infection time enrollment proven suspect related immunocompromise include HIV active recurrent Hepatitis B Hepatitis C. 6 . Systemic local treatment immune modulate agent dos systemic effect live vaccination within 3 month 7 . Stroke , myocardial infarction , acute coronary syndrome , revascularization procedure recurrent TIA within last 6 month . 8 . Unwillingness use insulin glargine additional medication glycemic control deteriorate . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>canakinumab</keyword>
</DOC>